LPCN Stock Overview A clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lipocine Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lipocine Historical stock prices Current Share Price US$4.58 52 Week High US$11.79 52 Week Low US$2.76 Beta 1.26 1 Month Change 0.88% 3 Month Change 5.77% 1 Year Change 64.16% 3 Year Change -75.28% 5 Year Change -36.31% Change since IPO -98.65%
Recent News & Updates
FDA Grants Fast Track Designation to Lipocine Inc. for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis Dec 18
Lipocine Inc. Announces Publication and Discussion of LPCN 1148 Manuscript at Liver Meeting 2024 Editor’s Cut Session Nov 21
Lipocine Inc. Announces Positive Oral Brexanolone Quantitative EEG Results Oct 10
Price target decreased by 35% to US$21.50 Sep 24
New major risk - Revenue and earnings growth Aug 12
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study Jun 25 See more updates
FDA Grants Fast Track Designation to Lipocine Inc. for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis Dec 18
Lipocine Inc. Announces Publication and Discussion of LPCN 1148 Manuscript at Liver Meeting 2024 Editor’s Cut Session Nov 21
Lipocine Inc. Announces Positive Oral Brexanolone Quantitative EEG Results Oct 10
Price target decreased by 35% to US$21.50 Sep 24
New major risk - Revenue and earnings growth Aug 12
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study Jun 25
Lipocine Inc. Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late-Breaking Session at EASL Congress 2024 Jun 13
First quarter 2024 earnings released: EPS: US$0.66 (vs US$0.74 loss in 1Q 2023) May 10
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 May 01
Lipocine Inc., Annual General Meeting, Jun 05, 2024 Apr 24
Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity Apr 11
Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis Mar 28
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 Mar 26
Price target decreased by 13% to US$33.00 Feb 15
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 Feb 06
New minor risk - Share price stability Jan 16
Consensus EPS estimates fall by 27% Nov 15
New major risk - Revenue and earnings growth Oct 30
Lipocine Inc. Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression Oct 28
New minor risk - Shareholder dilution Aug 14
Lipocine Inc. Announces Positive Topline Results from A Phase 2 Clinical Study of LPCN 1148 Jul 28
Consensus revenue estimates fall by 60% May 18
Consensus revenue estimates fall by 20% Mar 17
Lipocine Inc. Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis Dec 20
Lipocine Receives Non-Compliance Letter from Nasdaq Regarding an Additional 180-Day Grace Period Dec 08
Price target increased to US$3.83 Nov 16
Price target increased to US$3.83 Nov 11
Lipocine Inc. Announces Senior Leadership Appointments to Advance Its CNS-Focused Pipeline Nov 04
Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders Sep 27
Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% Sep 26
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) Sep 16
Price target decreased to US$3.33 Aug 08
Lipocine Inc. Announces U.S. Food and Drug Administration Accept Its Investigational New Drug Application Jul 12
Lipocine Receives Non-Compliance Letter from Nasdaq Jun 11
Consensus revenue estimates fall by 67% May 16
Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results May 13
Price target decreased to US$3.83 Apr 27
Insufficient new directors Apr 27
Lipocine Inc., Annual General Meeting, Jun 08, 2022 Apr 23
Lipocine Inc. Announces Board Appointments Apr 12
Lipocine Inc. Announces Its Partner Received FDA Approval of TLANDO™ Mar 30
Consensus forecasts updated Mar 16
Lipocine Inc. Announces Regulatory Guidance on LPCN 1144 in Non-Cirrhotic Nash Mar 03
Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet? Feb 22
Lipocine Inc. Announces Peer-Reviewed Publication of Positive Phase 3 Study Results for TLANDO Jan 28
Lipocine Inc. Announces Patient Dosed in its Phase 2 Study with LPCN 1148 for Management of Liver Cirrhosis Dec 23
No longer forecast to breakeven Nov 25
Price target decreased to US$3.75 Nov 10
Lipocine Inc. Announces FDA Affirmation of Class 1 NDA Resubmission for Tlando® Oct 01
Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly? Sep 14
Lipocine Inc. Announces Positive Topline 36-Week Results from Phase 2 Proof of Concept Lift Aug 26
No longer forecast to breakeven Aug 07
Consensus forecasts updated Aug 06
Lipocine Inc. Enters into Global Settlement and License Agreement with Clarus Therapeutics Inc. to Resolve All Outstanding Claims in On-Going Intellectual Property Litigation and Interference Proceeding Jul 15
Price target decreased to US$4.50 Jun 25
Lipocine Inc. Announces U.S. Food and Drug Administration Clears Investigational New Drug Application to Initiate A Phase 2 Study to Evaluate the Therapeutic Potential of LPCN 1154 Jun 15
Lead Independent Director Stephen Hill has left the company Jun 15
Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression Jun 14
Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment May 26
Lipocine competitor prevails in patent infringement lawsuit for Jatenzo May 26
When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit? May 11
Lipocine EPS beats by $0.01 May 06
Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic? Jan 26
New 90-day high: US$1.76 Jan 20
Lipocine Inc. Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications Jan 15
Lipocine Inc. Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed Nash Subjects Jan 13
Lipocine announces positive results from phase 2biopsy-confirmed NASH study Jan 12
Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study Dec 31
Price target raised to US$5.33 Dec 12
Lipocine Announces Tentative Approval of Tlando™ Dec 10
FDA Ok's Lipocine's testosterone replacement therapy, tentatively Dec 09
Co-Founder exercised options and sold US$68k worth of stock Dec 09
New 90-day high: US$1.69 Dec 08
Lipocine Provides New Regulatory Update on TLANDO™ Dec 06
Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry? Dec 04
Earnings beat expectations Nov 11
Lipocine EPS misses by $0.01 Nov 10
Lipocine Provides Regulatory Update on TLANDO™ Nov 07
Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and Nash At the Liver Meeting Digital Experience Nov 06
Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection Nov 06
New 90-day low: US$1.20 Oct 31
Lipocine Inc. to Present Data At the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America, Inc Oct 14
Lipocine Inc. Announces Completion of Enrollment in the LPCN 1144 Lift Study Sep 22
New 90-day high - US$1.53 Jul 21
Lipocine Regains Compliance with Nasdaq Minimum Bid Price Requirement Jul 17
Lipocine Inc.(NasdaqCM:LPCN) dropped from Russell Microcap Growth Index Jul 04 Shareholder Returns LPCN US Pharmaceuticals US Market 7D -4.6% -1.9% -1.1% 1Y 64.2% 6.5% 22.4%
See full shareholder returns
Return vs Market: LPCN exceeded the US Market which returned 23.7% over the past year.
Price Volatility Is LPCN's price volatile compared to industry and market? LPCN volatility LPCN Average Weekly Movement 10.7% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: LPCN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LPCN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor.
Show more Lipocine Inc. Fundamentals Summary How do Lipocine's earnings and revenue compare to its market cap? LPCN fundamental statistics Market cap US$25.46m Earnings (TTM ) -US$4.06m Revenue (TTM ) US$7.92m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LPCN income statement (TTM ) Revenue US$7.92m Cost of Revenue US$0 Gross Profit US$7.92m Other Expenses US$11.98m Earnings -US$4.06m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.76 Gross Margin 100.00% Net Profit Margin -51.19% Debt/Equity Ratio 0%
How did LPCN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 04:36 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lipocine Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Scott Henry Alliance Global Partners John Newman Canaccord Genuity Corey Davis Canaccord Genuity
Show 4 more analysts 
